Highlights
New Otago biotech startup targets cancer
Amaroq Therapeutics, a new biotech startup company with the goal of developing targeted drugs for cancer, has been awarded si...
read the full story
Chasing a cancer suspect to cytokinesis
A potential new way to target aggressive cancers has been identified through a MWC project as part of the research programme ...
read the full story
MWC continues to lead the way in NZ cancer vaccine research
Immune therapy is one of the most exciting and promising areas of cancer research. Around New Zealand, teams of Maurice Wilki...
read the full story
New imaging improves our understanding of the immune system
Maurice Wilkins Centre researchers have used novel imaging technology to reveal the structure and inner workings of entire ly...
read the full story
Building blocks for new medicines
The MWC uses New Zealand’s outstanding medicinal chemistry expertise to discover new medicines. A particular kind of chemistr...
read the full story
One cancer gene – but several different proteins
Cancer arises due to changes in DNA in a single cell. Many changes are needed over time to a cell’s DNA to make it cancerous...
read the full story
Turning the tables on cancer
Tumours often contain areas with less oxygen than is found in normal tissues. These areas are less vulnerable to many forms o...
read the full story
Mid-term review sets future direction
A comprehensive independent assessment found the Centre to be performing at a high level, producing distinct and positive ben...
read the full story
Smarter drug design
An advanced experimental technique linked to high powered computation is becoming an increasingly important tool for MWC rese...
read the full story
MWC welcomes landmark results for lung cancer drug
A novel lung cancer drug with strong development links to the MWC has shown impressive results in a large-scale international...
read the full story
Newly funded research highlights MWC collaborations
A five-year research programme aims to develop nontoxic vaccine technologies to complement existing cancer immunotherapies.
read the full story
The tumour-promoting activities of a famous protein
Developing new cancer therapies and a more reliable test for prostate cancer are just some of the potential outcomes of Mauri...
read the full story
MWC leads cancer immune therapy conversation
The Maurice Wilkins Centre continues to be part of an international drive to develop and improve immune therapy for cancer. I...
read the full story
Cancer drug advances to phase II clinical trials
A New Zealand cancer drug developed by two Maurice Wilkins Centre investigators has reached the second phase of clinical tria...
read the full story
New therapies - from a new generation (2013)
Nurturing the next generation of scientists is an important part of the Maurice Wilkins Centre’s work – and senior students c...
read the full story
New chemistry transforms cancer vaccine (2013)
A new kind of chemistry that dramatically simplifies the manufacture of cancer vaccines was created this year by Honours stud...
read the full story
Major new cancer vaccine programme (2010)
Maurice Wilkins Centre investigators are involved in a major new research programme that aims to develop and trial anti-cance...
read the full story
The future of vaccines (2012)
Maurice Wilkins Centre investigator Professor Sarah Hook from the University of Otago is developing new vaccine formulations ...
read the full story